Antimicrobial Susceptibility Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Antimicrobial Susceptibility Testing Market Trends and Insights

Escalating Global Antimicrobial Resistance Burden

The 2024 Global Burden of Disease study attributed 1.14 million direct deaths to AMR in 2021 and warned that cumulative mortality could hit 39 million by 2050 if current trends persist^{[1]The Lancet AMR Collaborators, “Global Burden of Bacterial Antimicrobial Resistance,” THELANCET.COM}. WHO’s 2025 GLASS report logged susceptibility data from 104 countries, up from 87 in 2023, and set a 2030 goal for 80% of members to achieve national diagnostic capacity. In India, intensive-care units reported New Delhi metallo-β-lactamase prevalence above 30%, driving calls for rapid carbapenem-sparing guidance. Europe’s EARS-Net processed 474,364 invasive isolates in 2024 and piloted cefiderocol panels to track resistance to last-resort agents. Yet fewer than 40% of labs in low-income countries can run standardized antimicrobial susceptibility testing (AST), leaving a gap for affordable, low-complexity platforms.

Pharmaceutical and Biotechnology Pipeline Integration of AST

Spero Therapeutics secured FDA approval in September 2024 for tebipenem HBr after Phase 3 trials that used real-time susceptibility data to refine dosing, trimming review timelines. GlaxoSmithKline’s gepotidacin program employed high-throughput AST to map resistance emergence and support 2024 breakpoint proposals to CLSI. FDA guidance issued that same year encourages co-submission of antimicrobials and companion AST assays, enabling synchronized market entry. Contract research organizations reported a 40% increase in AST service requests from biotech clients between 2023 and 2025, as investors demanded pharmacodynamic evidence ahead of Phase 2 funding rounds.

Precision Medicine Movement Toward Targeted Antimicrobial Therapy

The U.S. CDC launched its Electronic Test Orders and Results program in 2024 to directly integrate AST outputs into electronic health records, enabling earlier de-escalation of broad-spectrum therapy^{[2]Centers for Disease Control and Prevention, “Electronic Test Orders and Results Initiative,” CDC.GOV}. Thermo Fisher’s Sensititre platform is helping hospitals comply with Joint Commission stewardship criteria that require susceptibility-based audits. A 2025 systematic review found rapid AST cuts hospital stay by 1.2–2.5 days and saves USD 3,000–8,000 per sepsis patient in high-income settings. The European Medicines Agency began enforcing susceptibility testing before veterinary use of critically important antimicrobials in 2024. Despite clinical value, private U.S. insurers reimbursed fewer than half of rapid phenotypic AST claims outside bloodstream infections as of mid-2025.

Adoption of Rapid Phenotypic AST Platforms for Point-of-Care Decision Making

bioMérieux’s VITEK REVEAL, FDA-cleared in June 2024, delivers phenotypic results 5.5–6 hours after a positive blood culture, enabling same-day sepsis therapy optimization. Accelerate Diagnostics’ Pheno system produces identification and susceptibility results in approximately 7 hours, bypassing overnight incubation. BARDA funded Selux Diagnostics in 2024 to craft a sub-4-hour point-of-care AST device for emergency departments, citing a 7% mortality increase per hour of delayed appropriate therapy. T2 Biosystems received FDA clearance in 2024 for the T2Resistance Panel, which identifies 13 resistance genes in 3–5 hours directly from positive blood culture, eliminating subculture delays. The FDA demands evidence that rapid AST alters prescribing and improves outcomes, while raising development costs and lengthening the time-to-market.

High Upfront Instrumentation Costs and Limited Reimbursement Pathways

Automated AST systems often cost more than USD 100,000, while consumables run USD 15–30 per test; yet, U.S. Medicare reimburses rapid phenotypic AST at only USD 18–22, forcing hospitals to absorb these losses^{[3]Centers for Medicare & Medicaid Services, “Clinical Laboratory Fee Schedule CY 2024,” CMS.GOV}. As of mid-2025, private insurers covered fewer than 50% of claims, limiting uptake outside academic centers. India’s Atmanirbhar Bharat program funded USD 36.5 million for 12 reference labs—barely 0.1% of its estimated 100,000 labs—so most facilities still rely on 18- to 24-hour disk diffusion. A 2024 survey across Sub-Saharan Africa showed 60% of labs lack staff trained in automated AST, even when instruments are donated. Leasing and reagent-rental contracts ease capital expenditures (CAPEX) but shift costs to operational budgets, creating vendor lock-in.

Fragmented Global Regulatory and Breakpoint Harmonization Challenges

CLSI and EUCAST issued joint disk-potency procedures in 2025, yet interpretive criteria for agents such as cefiderocol still diverge, complicating multinational trials. EUCAST version 15.0, released in January 2025, updated eight drug–organism pairs, while CLSI’s M100-34 introduced alternate susceptible-dose-dependent categories in February, causing a one-month misalignment. FDA guidance advocates synchronous drug-diagnostic submissions, but regulatory calendars remain asynchronous. Genotype-phenotype discordance persists; a 2024 Nature study demonstrated that the detection of blaCTX-M did not always translate to phenotypic resistance, necessitating confirmation and incurring additional costs. Labs maintaining dual CLSI/EUCAST workflows double quality-control expenses and training requirements.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Automation Gains Traction but Manual Methods Linger

The segment generated the largest share in 2025, when manual procedures still accounted for 51.25% of the antimicrobial susceptibility testing market revenue, due to their low capital requirements. However, automated systems are forecast to advance at a 7.54% CAGR as laboratories chase faster turnaround times and data integration. bioMérieux’s VITEK COMPACT PRO, cleared in 2024, now ships with CLSI AUTO15-compliant autoverification, trimming errors tied to manual transcription. Consumables create sticky revenue; labs spend USD 15–30 per run on panels, media, and controls. Becton Dickinson’s EpiCenter software aggregates outputs across multiple hospitals, delivering stewardship dashboards that extend value beyond the hardware.

Capital constraints and regulatory inertia prolong manual usage, especially in low-income settings where national guidelines do not compel automation. Workforce shortages are shifting opinions: a 2024 cross-Africa survey found that 60% of lab directors viewed automation as a labor multiplier rather than a luxury. Vendors are also bundling identification and susceptibility; Bruker is adapting MALDI-TOF mass spectrometry to flag carbapenemase production, allowing laboratories to justify combined purchases. The dual benefit of speed and reduced hands-on time is expected to accelerate adoption, but success hinges on financing models that ease upfront cost burdens.

By Testing Type: Antibacterial Dominance Faces Emerging Pathogen Pressure

Antibacterial panels accounted for 42.43% of 2025 revenue, underscoring their centrality to clinical practice. Nonetheless, antiparasitic assays are the fastest-growing sub-segment, with a 7.66% CAGR, driven by WHO reports of partial artemisinin resistance in six African nations, which demand phenotypic confirmation of kelch13 mutations. Antifungal testing is gaining urgency after Candida auris outbreaks; the CDC counted 3,270 clinical U.S. cases in 2024, fueling hospital adoption of Thermo Fisher’s Sensititre YeastOne system. Automated antifungal panels remain under-penetrated, presenting a white space for vendors. Antiviral AST remains niche, primarily limited to HIV and influenza surveillance.

Mycobacterial testing operates in a separate regulatory lane through the WHO’s Global Laboratory Initiative, relying on MGIT liquid culture and requiring biosafety infrastructure that is often absent in many local labs. The market also lacks integrated molecular-plus-phenotypic platforms for malaria and other parasites, opening development opportunities funded by BARDA and the Wellcome Trust. Collectively, these trends diversify revenue streams away from mature antibacterial offerings.

By Application: Diagnostics Lead, Drug Discovery Accelerates

Clinical diagnostics retained 55.43% of 2025 revenue, as hospitals rely on AST to guide prescribing; however, drug discovery is projected to grow at an annual rate of 8.54% through 2031. Spero Therapeutics’ tebipenem approval demonstrated that real-time AST could shorten the regulatory review process, while GSK utilizes high-throughput susceptibility screens during lead optimization. CROs consequently report a 40% rise in AST outsourcing demand between 2023 and 2025. Public health surveillance relies on GLASS, which processed 23 million isolates in 2025, but still struggles with inconsistent species identification and breakpoint use.

Veterinary adoption is growing following the European Medicines Agency's mandate for susceptibility testing before dispensing critical antimicrobials to livestock, creating an incentive for VetCAST-aligned panels. Environmental monitoring is emerging: a 2025 Nature study detected 82 AMR genes in Indian sewage, spotlighting the need for tools that track resistance outside clinical settings. These diversified applications reduce reliance on hospital budgets and create multi-segment resilience.

By End User: Hospital Labs Dominate but Pharma Uptake Climbs

Hospitals supplied 41.63% of 2025 revenue, because stewardship mandates tie reimbursement to timely AST. Yet, pharmaceutical–biotech buyers are the fastest-growing cohort, with an 8.32% CAGR, as developers integrate susceptibility data into trials. Reference laboratories exploit economies of scale to handle antifungal and antiparasitic panels that small hospitals cannot maintain cost-effectively. Academic centers contribute to method development but represent modest commercial volume.

Hospitals wrestle with reimbursement gaps; Medicare’s USD 18–22 per rapid test often fails to cover consumables and depreciation costs, slowing uptake in community settings. Reference labs, such as Quest and LabCorp, invest in automation to boost throughput, but falling fee-for-service rates pressure their margins. Pharma users, by contrast, accept premium pricing because faster AST can shave months off drug-approval timelines, enabling vendors to charge for customized, high-throughput panels.

Geography Analysis

North America accounted for 42.95% of 2025 revenue, driven by CDC efforts to digitize test orders and results, as well as CPT codes that recognize rapid phenotypic AST. Still, reimbursement averaging USD 20 per test lags full cost recovery, limiting adoption to tertiary centers. Canada is piloting centralized provincial labs to serve remote regions, but differing reimbursement rules are slowing the national rollout. BARDA’s 2024 grant to Selux Diagnostics underlines the U.S. federal commitment to sub-4-hour sepsis testing.

Europe benefits from EUCAST’s annually refreshed breakpoints—version 15.0 added eight organism–drug pairs in 2025—and from EARS-Net surveillance, which covers 474,364 isolates. EMA rules now compel veterinary AST before prescribing the highest-priority antimicrobials, widening the customer base. Nonetheless, reimbursement disparities persist; Germany reimburses rapid AST under DRG, while southern Europe lacks dedicated codes. DARWIN EU real-world evidence supports post-market surveillance but has yet to harmonize payment models.

The Asia-Pacific region is the fastest-growing, forecast to grow at a 6.43% CAGR through 2031. India’s government allocated USD 36.5 million for 12 advanced microbiology centers, and China has integrated AST into provincial AMR surveillance. Japan’s universal coverage eases adoption, though hospital consolidation is shifting volumes to central labs. South Korea introduced tiered reimbursement in 2024 that pays more for rapid AST, aligning financial incentives with stewardship goals. However, rural labs still face staff shortages, echoing challenges seen in less developed regions. National AMR action plans in select emerging markets create smaller but notable growth pockets.

Regulatory Landscape

Antimicrobial susceptibility testing (AST) devices are regulated as in vitro diagnostics, with the United States primarily using the FDA 510(k) pathway under 21 CFR Part 866. In addition to device clearance by CDRH, FDA CDER is involved in establishing and updating antibacterial susceptibility test interpretive criteria (breakpoints), which drives label updates and panel content decisions for AST platforms used in clinical care and trials.

Standard-setting updates continue to affect compliance requirements and day-to-day workflows across regions. The FDA recognized CLSI M100 updates on an ongoing basis, and newer editions, including CLSI M100-Ed36 (published in January 2026), along with EUCAST breakpoint tables (with January 2026 validity of updated tables), increase the cadence of breakpoint change management for manufacturers and laboratories. In the European Union, IVDR (EU 2017/746) serves as the core framework for IVD market access, while EUCAST provides breakpoint and quality control guidance that laboratories and suppliers align to alongside country-specific implementation practices.

Market Opportunities and Future Outlook

A material whitespace remains in shortening time-to-actionable AST for acute care while maintaining results that hold up against reference standards and breakpoint updates. Recent clinical and proof-of-concept evidence points to how direct-from-sample and rapid phenotypic approaches can compress reporting timelines: a May 2026 clinical evaluation of the LifeScale AST system in Gram-negative bloodstream infections reported a median turnaround time of 8.6 hours versus 48.1 hours for standard methods, while February 2026 academic work on QolorPhAST described minute-scale workflows with reported agreement metrics for AST. These findings support earlier insertion of such systems into sepsis pathways, particularly as hospitals prioritize same-day decisions.

Regulatory and surveillance programs are also creating opportunities for vendors that can operationalize frequent breakpoint refreshes and support interoperability. FDA recognition of updated CLSI standards in 2026, including M100 and antifungal standards for yeasts and filamentous fungi, increases the value of software-led change control, autoverification, and panel update mechanisms that limit downtime when interpretive criteria change. On the demand side, WHO GLASS participation expanded to 141 countries and territories by late 2024, and ECDC initiated the EURGen-Net CRE25 survey in January 2026 across 37 countries, reinforcing the need for scalable AST data pipelines with consistent methodologies that can serve both routine diagnostics and resistance surveillance.